CD70 and CD80 are co-stimulatory molecules which belong to the tumor necrosis factor family and the B7 family respectively. When they are co-expressed by gene-modi®ed TS/A tumor cells, they provide an ef®cient protective and long-lasting T-dependent antitumor response. We ®rst showed that when CD70 and CD80 were delivered in the tumor environment by gene-modi®ed ®broblasts, but were not expressed by the tumor cells themselves, no antitumor response was observed. We next assessed whether the intracytoplasmic domains of CD70 and CD80 contribute to enhance the co-stimulatory activity necessary to induce effective T cell±tumor cell interactions and T celldependent antitumor response. TS/A cells were gene-modi®ed to express different combinations of deleted (CD70D and CD80D) or full-length CD70 and CD80 co-stimulatory molecules. In vitro, the CD80 intracytoplasmic domain was required to regulate CD80 membrane redistribution by interacting with the actin cytoskeleton. The loss of the CD70 intracytoplasmic domain did not alter its ability to relocate on the surface membrane, but failed to co-stimulate T cell proliferation. In vivo experiments in syngeneic BALB/c mice showed that the CD70/CD80-TS/A and the CD70D/CD80-TS/A tumors were rejected via CD8 T cells, whereas CD70/CD80D-TS/A and CD70D/CD80D-TS/A tumors were not. The mice that rejected CD70D/CD80-TS/A tumors showed decreased protection against injection of parental TS/A cells when compared to mice which rejected CD70/CD80-TS/A tumors. These results showed that the intracytoplasmic domain of CD80 was critical for the effector phase of CD8 T cell-dependent tumor rejection and that the CD70 intracytoplasmic domain could mediate proliferative or surviving signals required for optimal effector/memory CD8 T cell generation.
Introduction
A major focal point of cancer research is how tumors escape immune recognition and destruction. Advances in our understanding of T lymphocyte activation and co-stimulation have provided new strategies for developing tumor-speci®c immunotherapy. T cell activation depends on the interaction of several receptors on the T cell surface with their ligands on the antigen-presenting cells (APC). These interactions induce an antigen-speci®c signal delivered through the TCR and a second non-antigen speci®c`co-stimulatory signal' delivered by accessory receptors following their engagement with speci®c ligands expressed mostly by the APC. These interactions lead to the formation of a tight interface between a T cell and an APC (1±3) by the clustering of receptors and signaling molecules at the T cell±APC interface in discrete geometrical patterns (4±6).
CD80 is a co-stimulatory molecule which belongs to the Ig superfamily (B7 family) (7) . It is a monomeric surface glycoprotein expressed by activated B cells, T cells, monocytes and dendritic cells (DC) (8±10). Engaging CD80 through its ligand CD28 expressed by T cells simultaneously with TCR activation leads to the generation of T cell proliferation and cytokine production (i.e. IL-2) (7,11±13). CD28-mediated signals increase expression of Bcl-X L and promote survival of TCR-activated T cells (14) . Previous reports have shown that the triggering of both adhesion (LFA-1) and co-stimulatory (CD28) molecules by their speci®c ligands, respectively ICAM-1 and B7 molecules, is necessary and suf®cient to induce movement of the T cell cortical actin cytoskeleton toward the newly formed T cell±APC interface. This active accumulation of receptor pairs and other cytoskeleton-linked molecules by cortical actin polarization at the T cell±profes-sional APC (DC) interface requires active processes in both T cell and DC, and is necessary for T cell activation and proliferation (3, 5, 15, 16) . Furthermore, Doty and Clark (17, 18) have shown that the cytoplasmic tail of CD80 interacts with the actin cytoskeleton, in¯uences its subcellular location and affects the ability of CD80-transfected Reh cells to costimulate T cell proliferation in vitro. These in vitro studies suggest that CD80 could play an active role in the APC to provide an effective co-stimulatory signal to the CD28-expressing T cells.
CD70 is a type II transmembrane glycoprotein that belongs to the tumor necrosis factor (TNF) family (19±21). Its speci®c interaction with its ligand CD27 has been shown to support clonal expansion of both antigen-stimulated CD4 and CD8 T lymphocyte populations (19,20,22±24) , and to enhance the generation of cytolytic T cells (20, 25) . CD70±CD27 interactions also participate in the generation and long-term maintenance of T cell memory, in particular of CD8 T cells (26) . The CD27 signaling pathway appears different from that of CD28, as, in contrast to CD28, CD27 employs TRAF molecules to induce downstream signals, in particular TRAF-2 and -5 (27±29).
In a previous study, we showed that the expression of only one molecule (CD80 or CD70) by gene-modi®ed tumor cells was not suf®cient to induce an effective antitumor response in vivo. However, CD80 was able to cooperate with CD70 to induce tumor rejection and protective immunity when coexpressed by two low immunogenic tumor cells, the TS/A mammary adenocarcinoma cell line and the B16.K1 melanoma cell line, injected into syngeneic mice (30) .
The aim of this study was to show, using in vivo models, that the two intracytoplasmic domains of CD70 and CD80 have critical functions to activate the T cell-mediated immune response induced by CD28±CD80 and CD27±CD70 interactions. We evaluated whether the loss of CD70 and/or CD80 intracytoplasmic domains affected the cooperation between the two co-stimulatory molecules required to induce ef®cient tumor rejection. We generated original models of doubletransfected tumor cells expressing various combinations of full-length (CD70 and CD80) and deleted forms (CD70D and CD80D) of the two co-stimulatory molecules. Since both molecules were required for the induction of an effective and long-lasting immune response, our models allowed us to characterize the speci®c contribution of each molecule to the induction of the immune response in vivo.
We have shown that transfection of TS/A tumor cells by the deleted forms of CD70 and CD80 did not impair the expression level of these molecules. However, in vitro, under antibody treatment, the CD80 intracytoplasmic domain, but not that of CD70, was necessary for the molecule to become redistributed on surface TS/A cells by presenting intact actin cytoskeleton.
The CD70D/CD80D TS/A cells s.c. injected in immunocompetent syngeneic BALB/c mice formed tumors that were not rejected. These results showed that the loss of CD70 and/or CD80 intracytoplasmic domains led to an incomplete antitumor immune response. To evaluate the relative contributions of CD70 and CD80 intracytoplasmic domains, we compared the abilities of CD70/CD80D-TS/A-and CD70D/CD80-TS/Atransfected cells to induce an immune antitumor response in vivo. We showed that the CD80 intracytoplasmic domain, but not that of CD70, was necessary to induce CD8 T celldependent primary tumor rejection. The co-expression of fulllength CD70 molecules and CD80 molecules was required to co-stimulate T cell expansion, and to induce long-lasting antitumor responses. Understanding the role of CD28/CD80 and CD27/CD70 interactions in the regulation of these processes during T cell activation and antitumor response appears to be a critical issue in designing protocols improving antitumor immunity.
Methods

Animals
Female BALB/c mice were purchased from CERJ Janvier (Le Genest Saint-Isle, France). All mice were used for experiments at 6±8 weeks old according to European Community guidelines.
Retroviral constructs
The construction and characterization of the DFG human CD80 (DFGhCD80) and the DFG human CD70 (DFGhCD70) retroviral vectors have previously been described (31, 32) . These MFG-based retroviral vectors express these molecules along with a neo r or zeo r selectable marker, encoding resistance to G418 (Gibco/BRL, Cergy Pontoise, France) and zeocyn (Cayla, Toulouse, France) respectively. The control vector (mock) consists of the MFG retroviral vector with an IRES neo r sequence. The cDNAs encoding the deleted forms of CD80 (CD80D) and CD70 (CD70D) molecules were generated by PCR cloning from the respective full-length cDNAs. To delete the 17 C-terminal amino acids of CD80, a translation stop codon was introduced at the 3¢ end of the cDNA sequence corresponding to the end of the transmembrane domain to generate cytoplasmic-domain-deleted CD80. To obtain a CD70 cytoplasmic-domain-deleted form, we deleted the 16 N-terminal amino acids and introduced a new translation initiation codon upstream of the beginning of the transmembrane cDNA sequence. The following primers were used: CD80 sense primer (8S), 5¢-CCATGGGCCACACACGG-AGG-3¢ and CD80D anti-sense primer (8DAS): 5¢-CGGGAT-CCTCACTATCT GCATCTTGGGGCAAAGC-3¢; CD70D sense primer (7DS): 5¢-CATGCCATGGT CCTGCGGGCTGCTTTGG-TC-3¢ and CD70 anti-sense primer (7AS): 5¢-CGGGATCCC-TAATCAGCAGCAG-3¢. The forward primers all contained NcoI sites and the reverse primers all contained BamHI sites. These PCR products were cloned into the MFG-based retroviral vector containing an IRES neo r or IRES zeo r at Pennsylvania State University on February 20, 2013 http://intimm.oxfordjournals.org/ Downloaded from sequence to obtain the expression vectors DFG CD70D and DFG CD80D. All constructs were sequenced to con®rm sequence ®delity.
Antibodies
The mAb used to test co-stimulatory molecule cell-surface expression by¯ow cytometry analysis were FITC-conjugated mouse anti-human CD80 mAb (MAB 104) purchased from Immunotech (Marseille, France) and phycoerythrin (PE)-conjugated mouse anti-human CD70 mAb (Ki-24) purchased from BD Biosciences PharMingen (Le Pont de Claix, France). The mAb used to phenotype naive and memory T cells were PEconjugated rat anti-mouse CD8 (KT15) (Immunotech), CyChrome-conjugated rat anti-mouse CD44 (IM7), FITC-conjugated rat anti-mouse CD62L (MEL-14) and isotype controls (BD Biosciences PharMingen). After staining with the appropriate mAb, FACS analysis was conducted on a Coulter XL 4C (Beckman Coulter, Roissy CDG, France) coupled with System II acquisition software by using the WIN MDI 2.8 software.
Immuno¯uorescence staining for microscopy analysis was performed using mouse IgG anti-human CD70 mAb, mouse IgG anti-human CD80 mAb (MAB 104) (Immunotech), rabbit biotinylated F(ab¢) 2 anti-mouse IgG (Dako, Glostrup, Denmark) and avidin, Neutravidine±FITC conjugate (Molecular Probes, Leiden, The Netherlands).We used anti-mouse CD3e mAb (500A2) (BD Biosciences PharMingen) to perform in vitro lymphocyte stimulation. Rat anti-mouse CD8 (53-6.72) and rat anti-mouse CD4 (GK1.5) used in depletion experiments were puri®ed from ascitic¯uids of hybridoma cell lines obtained from the ATCC (Manassas, VA).
Cells
TS/A is a tumor cell line established by P. Nanni (Bologna, Italy) derived from a spontaneous mammary adenocarcinoma of the BALB/c strain (33) and kindly provided by P. Lollini (Bologna, Italy). TS/A tumor cells were transfected with combinations of the different retroviral vectors carrying the different forms of co-stimulatory molecules (CD70 or CD70D and CD80 or CD80D) using Lipofectamine (Gibco/BRL) as previously described (30) . The stably transfected cells CD70D/CD80D-TS/A, CD70/CD80D-TS/A and CD70D/CD80-TS/A were selected using G418 (1 mg/ml) and zeocyn (0.1 mg/ml). These cell lines and the stably transfected CD70-TS/ A, CD80-TS/A and CD70/CD80-TS/A cell lines (30) were cultured in RPMI 1640 medium (Gibco/BRL), supplemented with 2 mM glutamine and 10% FCS (Life Technologies, Cergy Pontoise, France). BALB/c ®broblasts are syngeneic to BALB/ c mice and were a gift from J. E. Gairin (Toulouse, France). BALB/c cells were co-transfected with DFGhCD70 IRES zeo r and DFGhCD80 IRES neo r using Lipofectamine. The stably transfected BALB/c CD70/CD80 cells were selected using G418 (0.5 mg/ml) and zeocyn (0.1 mg/ml). After cell selection, the expression of CD70 and CD80 was checked by¯ow cytometry as described previously (30) . MM45T.Li is a hepatocarcinoma tumor cell line purchased from the ATCC. These two cell lines were cultured in Dulbecco's modi®ed Eagle's growth medium (Gibco/BRL) supplemented with 10% FCS. All cell lines were tested periodically for mycoplasma using a DNA hybridization probe (Stratagene, La Jolla, CA) or Molli' technique (34).
RT-PCR
Cells were cultured in a T-75 cm 2 culture¯ask for 72 h until subcon¯uence. Total RNA was isolated from a cell suspension as described by Chomczynski and Sacchi (35) from 5 Q 10 6 cells using TRIzol reagent as described by the supplier (Life Technologies) and transcribed into cDNA using the Ready-ToGo kit (Amersham Pharmacia Biotech, Piscataway, NJ) and Random Primers purchased from Life Technologies. Ampli®cation of cDNA was conducted with 1 U/100 ml of Taq DNA polymerase (Roche Diagnostics, Mannheim, Germany) in a PTC-100 Programmable Thermal Controller (MJ Research, Watertown, MA) by 30 three-temperature cycles consisting of denaturation at 94°C (60 s), annealing at 65°C (60 s) and elongation at 72°C (60 s). The following primers were used: 8DAS, CD80 anti-sense primer (8AS): 5¢-CACTGTTATACAG-GGCGTACAC-3¢; 8DS, CD70 sense primer (7S): 5¢-CATGCC-ATGGCGGAGGAGGGTTCGGGCTG-3¢; 7DS and 7DAS antisense primer. PCR products and the fX174 DNA/HaeIII mol. wt marker (Promega, Lyon, France) were separated by electrophoresis through 2% agarose (Boehringer Mannheim, Mannheim, Germany) Tris±borate±EDTA (Interchim, Monluc Ë on, France) gels and visualized by staining with ethidium bromide (Promega, Lyon, France).
Immuno¯uorescence microscopy
The transfected TS/A cells were plated at a concentration of 10 5 cells/ml and cultured in RPMI 10% FCS for 48 h in a ®nal volume of 2 ml on 20-mm 2 micro cover glass (Erie Scienti®c, Portsmouth, NH) in six-well plates. After 48 h, the culture medium was removed and slides were washed 3 times with ice-cold staining buffer (5% FCS in PBS). Cells were stained at 4°C for 45 min with the primary antibody, anti-CD70 mAb (5 mg/ml) or anti-CD80 mAb (2 mg/ml) diluted in staining buffer. After two further washings with ice-cold staining buffer, cells were incubated for 45 min at 4°C with goat biotin-conjugated F(ab¢) 2 anti-mouse IgG (1/50), washed and incubated with streptavidin±FITC (1/100) for 40 min at 4°C. The cells were washed 3 times at 4°C. Cells on cover glass were incubated at 37°C with 2 ml RPMI 10% FCS in six-well plates for 1 h. For the experiments using the actin-destabilizing drug cytochalasin B (CCB; Sigma, St Quentin Fallavier, France), CCB (10 mg/ml) was added to the culture medium RPMI just before the 37°C incubation (36) . Cells were tested for viability (>60%) by Trypan blue dye exclusion before being ®xed. Stained cells were then ®xed in ice-cold PBS 3.7% paraformaldehyde. Disruption of the actin cytoskeleton was con®rmed by staining permeabilized treated cells with rhodamine±phalloidine (1/60) for 40 min at room temperature (data not shown) (37) . The cells were mounted on slides and single-color analysis was performed at Q1300 magni®cation on a Zeiss Axioskop microscope equipped with epi¯uorescence ®lters.
Proliferation assays
T cells from the inguinal and axillary lymph nodes of BALB/c mice bearing 12-to 15-day-old TS/A tumors were prepared as previously described (30) , and were brought to a concentration of 10 6 cells/ml in RPMI 1640 medium with 2 mM L-glutamine (Gibco/BRL) supplemented with 10% heat-inactivated FCS, 5 Q 10 ±5 M b-mercaptoethanol, 10 mM HEPES For in vivo CD4 or CD8 depletion experiments, BALB/c mice received six i.p. injections of 150 mg of anti-CD4 or anti-CD8 mAb from ascites or IgG rat control antibodies (Sigma) in 500 ml of PBS. Antibodies were given on days ±2, 1, 4, 8, 11 and 15 with respect to the s.c. injection of 10 5 transfected TS/A cells. Depletion was checked on day 11 by¯ow cytometry using FITC-conjugated anti-CD4 or FITC-conjugated anti-CD8 mAb purchased from BD PharMingen. The results are expressed as mean size (mm 2 ) of tumors from groups of four to ®ve mice each T SD. To perform the statistical analysis for depletion experiments, the tumor size was log transformed. Analysis was carried out by repeated measures ANOVA variance analysis and Tukey multiple comparison test. Difference was estimated signi®cant at P < 0.05.
Phenotypic analysis of effector/memory CD8 T cells
BALB/c mice which had rejected the transfected CD70/CD80 or CD70D/CD80 TS/A cells or control naive BALB/c mice of the same age were s.c. injected 25±30 days after the initial injection with 3 Q 10 5 TS/A parental tumor cells in both¯anks. After 12 days, lymph node cells were harvested and cultured (10 6 cells/ml) with 0.25 mg/ml anti-CD3e and Mit-C-treated parental or transfected TS/A cells (5 Q 10 5 cells/ml) in 24-well plates. After 3 days, cells were collected, stained with PEconjugated anti-CD8, FITC-conjugated anti-CD62L and CyChrome-conjugated anti-CD44 mAb, and analyzed bȳ ow cytometry after gating on live cells. Marker expression levels were determined after gating on positive CD8 T cells.
Results
Direct expression of CD70 and CD80 by gene-modi®ed TS/A tumor cells is required to induce an in vivo antitumor response
We tested whether the co-stimulatory signal delivered through the engagement of CD70 and CD80 by their ligands CD27 and CD28 expressed by T cells could be spatially dissociated from the TCR±antigen signal delivered to T cells by the TS/A MHC class I + MHC class II ± tumor cells via their MHC class I±antigen complex. (Fig. 1) that unlike CD70/ CD80-TS/A, tumor growth of the parental TS/A cells was not inhibited when the mice were co-injected with syngeneic CD70/CD80-transfected ®broblasts as compared with the tumor growth induced by the injection of TS/A cells alone or TS/A cells co-injected with mock BALB/c ®broblasts. We showed that CD80 and CD70 could not ef®ciently activate an antitumor response in vivo by interacting with their counterreceptors CD28 and CD27 when they are not directly coexpressed by tumor cells expressing the tumor antigen±MHC I complexes.
Elaboration of tumor cell lines which expressed different combinations of full-length or intracytoplasmic domaindeleted CD70 and CD80 co-stimulatory molecules
In order to determine the respective roles of the intracytoplasmic domain of the two co-stimulatory molecules CD70 and CD80 in the induction of an effective T cell-dependent antitumor response, we constructed tumor cells which express co-stimulatory molecules deleted for their intracytoplasmic domain.
The TS/A tumor cells were stably co-transfected with MFG-derived vectors encoding either full-length CD70 (CD70) or a cytoplasmic-deleted form of CD70 (CD70D) and full-length CD80 (CD80) or a cytoplasmic-deleted form (CD80D) along with a neo r or zeo r selectable marker. We thus generated CD70D/CD80-TS/A, CD70/CD80D-TS/A and CD70D/CD80D-TS/A cells. After selection with the appropriate antibiotics (G418 and zeocyn), the stably transfected cells were checked for expression of the different combinations required, by RT-PCR using speci®c primers. As con®rmed in Fig. 2 , the CD70D-and CD80D-transfected cells only expressed mRNA encoding the cytoplasmicdeleted form of the respective co-stimulatory molecules. Indeed, no ampli®cation by PCR occurred when we used the couple of primers speci®c for the wild-type cDNA in the CD70D-or CD80D-transfected cells. In contrast, when cells were transfected with wild-type CD70 or CD80 cDNAs, each couple of primers (wild-type or deleted) gave rise to an ampli®cation band by PCR (Fig. 2) .
CD70D/CD80-TS/A, CD70/CD80D-TS/A and CD70D/ CD80D-TS/A cell clones were chosen by¯ow cytometry to express high amounts of either deleted or wild-type CD70 and CD80 molecules (Fig. 3) . The deletion of the cytoplasmic domains of CD70 or CD80 did not alter the membrane expression level of these molecules as CD70D/CD80-, CD70/CD80D-and CD70D/CD80D-transfected TS/A cells showed high mean¯uorescence intensity for the two costimulatory molecules when analyzed by¯ow cytometry (Fig. 3) .
Antibody-induced membrane CD70 and CD80 redistributions are differently affected by the loss of their intracytoplasmic domains and by disorganization of the actin cytoskeleton
We wanted to assess whether the delivery of a co-stimulatory signal to T cells could be affected by the loss of the CD80 or CD70 intracytoplasmic domains, and could be related to different surface membrane redistribution properties to re¯ect T cell and tumor cell interactions.
The CD80 intracytoplasmic domain has been shown to be required for membrane re-localization of CD80 via interaction with the actin cytoskeleton and to play a role in the CD28-dependent T cell activation process in vitro (17) . Using immuno¯uorescence assays, we followed the membrane redistribution of full-length and deleted CD80 or CD70 molecules on transfected TS/A cells after induction by speci®c antibodies. TS/A cells which presented distinct patched uorescence staining following incubation with the speci®c antibody were scored as positive for clustering, whereas homogeneous diffuse membrane staining distribution was scored as negative.
As shown in Fig. 4 , CD70 and CD80, either full-length or deleted, presented the same diffuse membrane distribution pro®le at time 0. After 1 h of incubation at 37°C, CD70-or CD80-stained CD70/CD80-TS/A cells showed respectively 100 and 83% of the cells with relocalization of CD70 or CD80 from a diffuse pattern to a clustered pattern ( Fig. 4A and B) . The cells expressing the deleted form of CD80 showed reduced formation of mAb-induced CD80 clusters (50.33%, Fig. 4A ). In contrast, CD70 clustering was not affected by the loss of its intracytoplasmic domainÐ100% of the CD70D/ CD80D-TS/A cells showed a CD70-clustered membrane distribution after the 1 h incubation at 37°C (Fig. 4B ). CD70D and CD80D molecules showed the same distribution pro®les in the CD70D/CD80 and CD70/CD80D-TS/A cells (data not shown).
CCB is known to prevent F-actin formation and surface receptor clustering (17, 36) . To test whether the membrane redistribution of CD80 and CD70 could be related to possible interactions of CD70 or CD80 cytoplasmic domains with the actin cytoskeleton, we examined the effects of inhibiting the formation of transfected TS/A ®lamentous actin with CCB before inducing membrane redistribution of full-length or deleted forms of CD70 or CD80.
As shown in Fig. 4(B) , disorganization of the actin cytoskeleton by CCB did not alter the ability of CD70 or CD70D to be redistributed under mAb treatment on surface membrane after 1 h at 37°C. On the other hand, treatment of CD80-expressing cells for 1 h with CCB reduced the number of cells with CD80-clustered formation (43.7%). This result was comparable with what was observed at 1 h for the CD80D-expressing cells (50.3%) and the CCB-treated CD80D cells (40%) (Fig. 4A) .
These data showed that CD70 and CD80 were relocated after 1 h incubation at 37°C at the surface membrane under mAb activation. The deletion of the intracytoplasmic domain of CD70 or the destabilization of the actin cytoskeleton did not alter its redistribution. The intracytoplasmic domain deletion of CD80 or the inhibition of the actin cytoskeleton (Fig. 5) . The proliferation rate of lymph node cells stimulated by CD70D/CD80D-TS/A was not signi®-cantly increased compared to the CD70-TS/A group, whereas 6 and 7) , CD70D/CD80-(lanes 8 and 9) and CD70/CD80D-(lanes 10 and 11) transfected TS/A tumor cells were extracted and used for RT-PCR as described in Methods. To analyze CD70 and CD80 deletions, pairs of speci®c primers were designed to amplify the deleted and/or the full-length cDNA of each co-stimulatory molecule (A). For CD70 (B), two pairs of speci®c primers were used, the sense primer 7S and the anti-sense primer 7AS (lanes 1, 4, 6, 8 and 10 ), which amplify only the wild-type CD70 cDNA, or the sense primer 7DS and the anti-sense primer 7AS (lanes 2, 5, 7, 9 and 11), which amplify both the wild-type CD70 cDNA (CD70) and the deleted form of CD70 cDNA (CD70D). The CD80 deletion (C) was analyzed by using two pairs of speci®c primers, the sense primer 8S and the anti-sense primer 8AS (lanes 1, 4, 6, 8 and 10 ), which amplify only the wild-type CD80 cDNA, or the sense primer 8S and the anti-sense primer 8DAS (lanes 2, 5, 7, 9 and 11), which amplify both the wild-type CD80 cDNA (CD80) and the deleted form of CD80 cDNA (CD80D). PCR products and the fX174 DNA/HaeIII mol. wt marker (lane 3) were analyzed by electrophoresis through 2% agarose Tris±borate±EDTA gels and visualized by incubation with ethidium bromide. (Fig. 5) .
The tumor rejection process required an intact CD80 intracytoplasmic domain
To test the ability of the deleted forms of CD70 and CD80 molecules to elicit an effective antitumor response, we compared the tumor growth of the mock-TS/A-, CD70/CD80-TS/A-and, in order to exclude a clone-speci®c response, three different clones of CD70D/CD80D-TS/A-transfected cells after s.c. injection into syngeneic BALB/c mice (Fig. 6A) . Even if a delay in tumor growth rate of CD70D/CD80D-TS/A cells was observed with regard to the mock-TS/A growth rate, the expression of the deleted forms of CD70 and CD80 by TS/A cells did not induce tumor rejection as full-length CD70 and CD80 did (Fig. 6A) .
To analyze which transfected co-stimulatory molecule is mainly involved in the tumor rejection, the tumor growth of CD70/CD80D-TS/A-and CD70D/CD80-TS/A-transfected cells was monitored after s.c. injection into BALB/c mice (Fig. 6B) . CD70/CD80D-TS/A cell injection induced the development of tumors with a growth rate similar to what was observed with CD70D/CD80D-TS/A cell injection (Fig. 6A and B) , whereas CD70D/CD80-TS/A cells were rejected by the injected mice (Fig. 6B) .
The percentages of mice which rejected the transfected TS/A cells are represented in Fig. 6(C) . The co-expression of the deleted or the full-length CD70 with full-length CD80 induced the rejection of the transfected tumor cells within 15 days post-injection for >90% of the injected mice (n = 18 mice for CD70D/CD80-TS/A and n = 20 for CD70/CD80-TS/A). CD70D/CD80D-TS/A cells were rejected only in 17% of the injected mice (n = 53). When TS/A cells expressed the CD80-deleted form, even with the wild-type CD70 molecule, only 15% of the injected CD70/CD80D-TS/A mice remained tumor free (n = 20). These results showed that the CD70/CD80 tumor rejection process required the intracytoplasmic domain of CD80 molecule, but not the CD70 intracytoplasmic domain (Fig. 6C) .
The speci®c protective antitumor response is affected by the loss of the CD70 cytoplasmic domain
Mice that did not develop tumors after the primary injection of transfected TS/A cells were challenged with wild-type TS/A cells and MM45T.Li tumor cells. Thirty days after the TS/A cell injection, only 39% of the CD70D/CD80-TS/A primary injected mice (n = 18) remained TS/A tumor free, whereas 80% of CD70/CD80-TS/A primary injected mice (n = 20) rejected tumor challenge (Fig. 7) . CD70D/CD80-TS/A cells retained the ability to stimulate immune effector cells responsible for tumor rejection, but were less effective than CD70/CD80-TS/A to generate a protective, long-lasting antitumor response to a subsequent challenge of wild-type TS/A cells (P = 0.01, c 2 -test). This protective immune response was speci®c as all the mice injected in the contra-lateral¯ank with unrelated MM45T.Li hepatocarcinoma tumor cells (H-2K d ) developed tumors ( Table 1 ). The partial antitumor response observed for CD70/CD80D-TS/A and CD70D/CD80-TS/A (Fig. 6C and 7) showed that the loss of CD70 and CD80 cytoplasmic domains impaired the co-stimulatory signal delivered to the immune system at different stages of the antitumor response.
CD8 T cells are necessary to mediate tumor rejection
Our previous work in nude mice has shown that the control of CD70/CD80-TS/A tumor growth observed in immunocompetent BALB/c mice was dependent on the T cells (30) . We evaluated which T cell populations could be speci®cally involved in the antitumor immune response mediated by costimulatory molecule expression and affected by the loss of the CD70 or CD80 intracytoplasmic domain. We compared the (Fig. 8) . In CD8-depleted BALB/c mice, CD70/ CD80-TS/A and CD70D/CD80-TS/A cells formed tumors that were not rejected in all the injected mice (Fig. 8A) . The CD8 T cells were involved in TS/A tumor growth control even if the costimulatory molecules were expressed without an intact intracytoplasmic domain (P < 0.05). The tumor growth of CD70/CD80-TS/A cells in CD8 T cell-de®cient mice was slower than the CD70D/CD80-TS/A and mock-TS/A tumor growth in CD8-de®cient mice (Fig. 8A ). These data suggest that an immune cell population other than CD8 T cells could be stimulated by CD70/CD80-TS/A cells. The similarity of growth between CD70/CD80D-TS/A cells in non-depleted mice and Tumor growth of CD70D/CD80-TS/A cells and CD70/CD80-TS/A cells was abrogated in control and in CD4-depleted mice, but rejection occurred later, delayed from day 11 to, 20 for the CD70D/CD80-TS/A tumors (Fig. 8B) . CD70/CD80D-TS/A tumor growth in CD4 T cell-de®cient mice was transiently increased compared to CD70/CD80D-TS/A tumor growth in IgG control mice (Fig. 8B) .
CD70/CD80-TS/A cells stimulate IFN-g secretion by CD8 T cells better than CD70D/CD80-TS/A cells
In vivo rejection of both CD70/CD80-TS/A and CD70D/CD80-TS/A tumors was CD8 T cell dependent. We hypothesized that the lack of an antitumor memory response in the CD70D/CD80-TS/A group could be related to the lack of additional CD8 T cell stimulation after the primary antitumor response. We then compared the co-stimulatory signals provided in vitro by the CD70/CD80-TS/A and CD70D/CD80-TS/A tumor cells to total lymph node cells or to CD8 T cells isolated from mice bearing 12-day-old parental TS/A tumors. T cells sensitized in vivo to TS/A cells were stimulated in vitro with various doses of Mit-Ctreated wild-type or gene-modi®ed tumor cells without antiCD3e. After 3 days of culture, IFN-g secretion was quanti®ed in culture supernatants by sandwich ELISA. As shown in Fig. 9 , the stimulation of CD8 T cells or total lymph node cells by CD70/CD80-TS/A cells induced stronger IFN-g secretion than CD70D/CD80-TS/A stimulation.
Interestingly, the CD70/CD80-TS/A stimulation of total lymph node cells induced stronger IFN-g secretion than stimulation of CD8 T cells alone. These data show that CD70/CD80-TS/A cells directly induced a stronger co-stimulation to CD8 T cell than CD70D/CD80-TS/A cells did. CD70 intracytoplasmic domain with CD80 appeared critical to co-stimulate the IFN-g production by CD8 T cells. However, this effect seemed potentiated by stimulation of other immune cell populations.
CD70/CD80-TS/A cells promote expansion of CD44 high CD62L low effector/memory CD8 T cells
We studied by¯ow cytometry analysis the CD44/CD62L effector/memory marker expression (38, 39) on CD8 T cells after in vitro stimulation. Lymph node cells were harvested from mice bearing 12-day-old parental TS/A tumor, and were cultured with anti-CD3e and Mit-C-treated CD70D/CD80-TS/A or CD70/CD80-TS/A cells for 3 days. As shown in Fig. 10 , lymph node cells stimulated in vitro with Mit-C CD70/CD80-TS/ A cells displayed a higher percentage of CD8 T cells expressing the CD44 high CD62L low phenotype (37.7 T 1.17%) compared to the Mit-C CD70D/CD80-TS/A stimulation The role of CD70 and CD80 intracytoplasmic domains in tumor rejection 367 at Pennsylvania State University on February 20, 2013 http://intimm.oxfordjournals.org/ Downloaded from (21.6 T 2.75%). The increased percentage of effector/memory CD8 T cells in total lymph node population after CD70/CD80-TS/A stimulation resulted both in an increased number of surviving CD8 T cells, and in an increased proportion of CD8 T cells expressing high CD44 and low CD62L markers (Table 2) .
These results re¯ected the higher capacity of CD70/CD80-TS/A tumor cells to expand effector and potentially memory CD8 T cells during the primary antitumor response.
We then studied the CD44/CD62L effector/memory marker expression on CD8 T cells during the secondary antitumor responses against parental TS/A tumor cells elicited in CD70D/ CD80 mice and CD70/CD80 mice. Twenty-seven days after the initial injection of the CD70/CD80-TS/A or CD70D/CD80-TS/A cells, mice which had rejected the transfected tumors were challenged with parental TS/A cells. Twelve days after, lymph node cells were harvested,and stimulated in vitro for 3 days with anti-CD3e and Mit-C-treated TS/A cells. Lymph node cells from mice which had rejected the CD70/CD80-TS/A tumors displayed, after in vitro stimulation with parental TS/A cells, a higher percentage of CD44 high CD62L low CD8 + T cells (26.3 T 2.29%) than lymph node cells from mice which had rejected CD70D/CD80 TS/A tumors (21.6 T 2.76%) ( Table 2 ). These data suggest that CD70/CD80 co-stimulation in vivo favored the in vitro expansion of CD44 high CD62L low CD8 T cells in response to the parental TS/A tumor cells and anti-CD3e stimulation compared to CD70D/CD80 co-stimulation.
Discussion
As CD70 and CD80 belong to different co-stimulatory families, the TNF family (19) and the B7 family respectively (7), they are expected to act at different stages of the antitumor response. CD80, mostly expressed by activated APC (40) , is known to be involved in the activation phase of naive T cells inducing, via CD80±CD28 interactions, IL-2 production and proliferation, and favoring cytotoxic T cell generation (41) . The CD70-dependent co-stimulatory signal has been shown to be involved after antigen-speci®c T cell stimulation, and to induce clonal expansion of the antigen-activated CD4 and CD8 T cell by direct LT±LT cell or T±B cell interactions (24, 26, 42) . Hendricks et al. have recently shown that CD27 is involved in the generation of T cell memory to in¯uenza virus, most likely due to enhanced T cell survival and/or expansion of memory T cell populations (26) .
The necessity of an intact intracytoplasmic domain in CD80 biological activity was controversial at the beginning of our studies. The CD80 intracytoplasmic domain was initially shown to be required to regulate in vitro CD80 redistribution and T cell co-stimulation when expressed by gene-modi®ed CHO and Reh cells (17, 18) . Recently, Faas et al. have described an alternative spliced soluble form of the porcine CD80 molecule that lacks both the transmembrane and intracytoplasmic domains, but which still interacts with both porcine and human CD28 and CTLA-4. This soluble form of CD80 could inhibit the in vitro proliferation of human CD4 T cells and block IL-2 production from human phytohemagglutinin-stimulated T cells (43) . These two points suggest that the intracytoplasmic domain of CD80 could be involved in an ef®cient CD80/CD28 T cell co-stimulation signal. In contrast, Yu et al. (1998) have shown that the intracytoplasmic domain of CD80 was not involved in vivo to induce tumor rejection of CD80 gene-modi®ed EL4 cells (44) .
In vitro, as previously shown, we con®rmed that CD80 membrane redistribution in TS/A cells also required an active process involving an interaction of the CD80 intracytoplasmic domain with the actin cytoskeleton. Previous studies have shown the involvement of the actin cytoskeleton of the professional APC (DC) in the priming of naive CD4 T cells in vitro (16) . Our results suggest that actin cytoskeleton interactions with the CD80 intracytoplasmic domain in a tumor cell could be implicated in the delivery of an effective CD28-dependent stimulatory signal to CD8 T cells. In vivo, we have shown for the ®rst time that the CD80 intracytoplasmic domain was critical to induce CD8 T cell-dependent tumor rejection of the gene-modi®ed TS/A tumors, CD70/CD80-TS/A and CD70D/CD80-TS/A. However, the expression of CD80 alone without CD70 on TS/A cells was not able to induce tumor rejection and only slowed down tumor growth (30) .
We showed that the CD70 membrane redistribution induced by mAb was independent of its intracytoplasmic domain and of the actin cytoskeleton. However, its ability to deliver in vitro a co-stimulatory proliferation signal with CD80 to TCR±CD3e-activated T cells was dependent on its intracytoplasmic domain. This result suggests a direct link between the intracytoplasmic domain of CD70 and its biological activity unrelated to the clustering. The CD70 molecule is physiologically transiently up-regulated on CD4 or CD8 T cells and B cells after stimulation (45±48) to induce clonal expansion of the antigen-activated CD4 and CD8 T cells by direct T±T cell or T±B cell interactions (21, 46, 49, 50) . These lymphoid cells have different cytoskeleton characteristics compared to the adherent DC expressing CD80, which are the most potent APC to activate naive T cells (16,51±53) . The different requirement of the CD70 or CD80 intracytoplasmic domain to induce the membrane redistribution pro®les observed in this study could be related to these morphological features.
The co-expression of CD70 and CD80D or of CD70D and CD80D by TS/A cells generated a delay of tumor growth, but no tumor rejection. These results suggest that the full-length CD70 molecule was not able, without the wild-type CD80 molecule, to induce tumor rejection. CD70/CD80 and CD70D/ CD80 tumor rejections were both dependent on the activation of CD8 effector T cells (Fig. 8A) . However, in the CD8 T celldepleted mice, CD70/CD80-TS/A tumors grew slower than the CD70D/CD80-TS/A tumors (Fig. 8A) . Furthermore, CD70/ CD80, but not CD70D/CD80, co-stimulation in vitro was more effective on total lymph node cells than on CD8 T cells to induce IFN-g secretion (Fig.9) . These ®ndings suggest that the full-length CD70 molecule with CD80 could be necessary to co-stimulate non-CD8 T cell populations with antitumor activities. In CD4-depleted mice, CD70/CD80-TS/A and CD70D/ CD80-TS/A tumors were still rejected, but the rejection time was delayed (Fig. 8B) . We observed by immunocytoanalysis, a CD4 T cell in®ltrate at day 8 post s.c. injection in tumors expressing CD70/CD80-TS/A and CD70/CD80D-TS/A compared to mock-TS/A cells (data not shown). However, in vitro, no CD4 T cell proliferation was observed when total lymph node cells were stimulated with anti-CD3e and Mit-C CD70/ CD80-TS/A cells (data not shown). NK cells express CD27 and CD28 (54, 55) , and so could potentially be activated by CD70/ CD80 TS/A cells. In vitro experiments have shown that CD27 or CD28 triggering on NK cells by CD70 or CD80 gene-modi®ed tumor cells stimulates NK cell proliferation and IFN-g secretion (54, 56, 57) . Recent ®ndings have shown that CD70 expression by gene-modi®ed MHC I-de®cient murine T lymphoma cells (RMA-S) induced in vivo NK-dependent tumor rejection (56) . This primary NK-dependent antitumor response elicited by CD70 expression by tumor cells played a major role in promoting T cell antitumor immunity against rechallenge with parental MHC I-suf®cient RMA tumor cells (56) .
These results are consistent with a model which assigns the CD80D-ineffective primary antitumor response to decreased capacities of CD80D to undergo mAb-induced clustering by its inability to interact with the tumor cell actin cytoskeleton. The APC cytoskeleton, in particular actin micro®laments and myosin motors, is thought to play a key role in driving the redistribution of synapse molecules. Overall, the changes in the cytoskeleton likely serve to increase the contact between TCR and MHC, and provide an optimal environment for signaling molecules downstream of the TCR and perhaps of the co-stimulatory molecules such as the ligands used in our models. For tumor cells expressing CD80 without its intracytoplasmic domain (CD70/CD80D-TS/A and CD70D/CD80D-TS/ A tumors), even if a slowing down of tumor growth was observed compared to mock-TS/A cells, the activation threshold appeared too low to generate effective T cell responses leading to tumor rejection.
The intracytoplasmic domain of CD70 expressed by tumor cells along with CD80 expression near tumor antigen appeared to be involved in mediating long-lasting antitumoral immunity. The mice which rejected CD70D/CD80-TS/A tumors were partially protected against a rechallenge with the wildtype TS/A cells. This incomplete immune response observed with CD70D/CD80-TS/A cells could be related to the inability of the intracytoplasmic domain-deleted CD70 to deliver a costimulatory signal involved in the generation of memory T cells relative to its inability to induce optimal T cell proliferation or survival signals as suggested by our in vitro data (Figs 5, 9 and 10). In vitro co-stimulation of lymph node cells with CD70 and CD80 molecules, but not CD70D and CD80 molecules, induced IFN-g secretion (Fig. 9) , and contributed to the expansion of CD8 T cells displaying an effector and potentially memory CD44 high CD62L low phenotype (38, 39) during the primary antitumor response (Fig. 10) .
In vivo, CD70/CD80 co-expression, like CD70D/CD80 coexpression, by transfected TS/A cells induced comparable CD8 T cell-dependent tumor rejection rates during the primary antitumor response. When direct¯ow cytometric analysis of CD8 T cell phenotype was conducted on lymph node cells harvested from CD70/CD80 and CD70D/CD80 mouse groups, 30 days after the initial injection time, after in vivo TS/A rechallenge, no difference was observed between the two groups (data not shown). After 3 days in vitro Mit-C TS/A stimulation, lymph node cells from the CD70/CD80 mouse group displayed higher numbers of CD8 T cells expressing the effector/memory CD44 high CD62L low phenotype than lymph node cells from the CD70D/CD80 mouse group (Table 2) . These data support the hypothesis that CD70/CD80 costimulation in vivo could improve the number of CD8 T cells potentially active against parental TS/A tumor cells by survival or expansion signals.
This work suggests that the full-length CD80 molecule along with CD70 expressed by the gene-modi®ed tumor cells could provide, at the tumor site, additional stimulation to T cells to favor their full maturation into effector cells, whereas the CD80 molecule without its intracytoplasmic domain with full-length CD70 does not. The two co-stimulatory molecules, CD70 and CD80, acted both on T cell populations with a predominant requirement of the CD80 intracytoplasmic domain to fully activate CD8 effector T cells and a potential requirement of CD70 for the activation or expansion of memory T cells. Recent ®ndings in 4-1BBL ±/± knockout mice have shown that, during BALB/c mice which were tumor free 30 days after being s.c. injected with 10 5 CD70/CD80-TS/A or CD70D/CD80-TS/A tumor cells and naive BALB/c mice (none) were s.c. injected with 3 Q 10 5 TS/A cells in both¯anks. After 12 days, total lymph node cells from a pool of two BALB/c mice per group were stimulated in vitro with Mit-C-treated parental, CD70D/CD80-TS/A or CD70/CD80-TS/A cells and 0.25 mg/ml anti-CD3e. After 3 days, cells were collected, stained with PE-conjugated anti-CD8, FITC-conjugated anti-CD62L and CyChrome-conjugated anti-CD44 mAb, and analyzed by¯ow cytometry after gating on live cells. Marker expression levels were determined after gating on CD8 + T cells. Data are expressed as the mean T SD of two separate in vitro stimulations representative of two other experiments.
a Values signi®cantly different (P < 0.01) from the BALB/c mice control group stimulated in vitro with the Mit-C-treated parental TS/A cells by Fisher's exact test.
at Pennsylvania State University on February 20, 2013 http://intimm.oxfordjournals.org/ Downloaded from in vivo secondary response to in¯uenza infection, the expansion level of the speci®c CD8 T cells is reduced to the level of a primary response (58) . The LCMV-infected 4-1BBL ±/± mice showed a general defect in expansion of the CD44 high subset of CD8 T cells compared to wild-type mice (58) . These data support the hypothesis that members of the TNF receptor family, like CD27, OX40 (59) or 4-1BB (58, 60, 61) , could sequentially act on T cells after CD28 co-stimulation to sustain the CD28-dependent T cell activation and differentiation signals by providing survival signals increasing or stabilizing T cell effector/memory numbers later in the response. The precise molecular signals required to induce each of the costimulatory pathways remain to be fully elucidated. These questions are central to our understanding of how genemodi®ed tumor cells are ef®cient immune stimulators and will help to de®ne more precisely how optimal triggering of a speci®c antitumor response occurs.
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